Pershing Edward Files SC 13D for Provectus Biopharmaceuticals

TL;DR

Pershing Edward just filed a 13D on Provectus Biopharma. Big ownership change incoming.

AI Summary

On June 26, 2024, Pershing Edward filed an SC 13D amendment regarding Provectus Biopharmaceuticals, Inc. The filing indicates a change in beneficial ownership of the company's common stock. The specific details of the change in ownership, including the exact number of shares and percentage of ownership, are not fully detailed in this excerpt.

Why It Matters

This filing signals a potential shift in control or significant stake acquisition in Provectus Biopharmaceuticals, Inc., which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — SC 13D filings often indicate significant changes in ownership or activist investor involvement, which can lead to increased volatility.

Key Players & Entities

• Provectus Biopharmaceuticals, Inc. (company) — Subject Company
• Pershing Edward (person) — Filing Person
• Heather Raines (person) — Authorized Contact
• June 26, 2024 (date) — Date of Event

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
• $1,660,000 — k which are issuable upon conversion of $1,660,000 aggregate principal amount of convertib
• $5,082,500 — on The Issuer has issued an aggregate $5,082,500 principal amount of secured convertible
• $3,447,500 — s from April 13, 2018 to June 30, 2024, $3,447,500 principal amount of the Notes plus inte
• $2.862 — Stock”) at a conversion price of $2.862 per share in accordance with the terms
• $125,000 — te in the aggregate principal amount of $125,000 held by the Reporting Person automatica
• $325,000 — m the Issuer in the principal amount of $325,000 pursuant to the Issuer’s 2022 Fin
• $50,000 — m the Issuer in the principal amount of $50,000 pursuant to the Issuer’s 2022 Fin
• $200,000 — te in the aggregate principal amount of $200,000 held by the Reporting Person automatica

Filing Documents

• formsc13d.htm (SC 13D) — 74KB
• 0001493152-24-026262.txt ( ) — 75KB

From the Filing

SC 13D 1 formsc13d.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __) Provectus Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74373P108 (CUSIP Number) Heather Raines 800 S. Gay Street, Suite 1610 Knoxville, TN 37929 (866) 594-5999 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 26, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 2 of 6 SCHEDULE 13D CUSIP No. 74373P108 1 NAMES OF REPORTING PERSONS Edward Pershing, CPA 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) PF, BK 5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION U.S.A. NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 22,472,700 (1) 8 SHARED VOTING POWER 162,350 (2) 9 SOLE DISPOSITIVE POWER 22,472,700 (1) 10 SHARED DISPOSITIVE POWER 162,350 (2) 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 22,635,050 12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.17% 14 TYPE OF REPORTING PERSON (See Instructions) IN (1) Includes 176,000 shares of common stock owned directly by the Reporting Person, 2,822,030 shares of common stock owned by the Reporting Person through a retirement plan, 13,674,530 shares of common stock issuable upon conversion of 1,367,453 shares of Series D-1 Convertible Preferred Stock held by the Reporting Person, and 5,800,140 shares of common stock issuable upon conversion of 580,014 shares of Series D-1 Convertible Preferred Stock which are issuable upon conversion of $1,660,000 aggregate principal amount of convertible promissory notes held by the Reporting Person. (2) Includes 60,600 shares of common stock owned by the Reporting Person’s spouse, 16,500 shares of common stock owned by the Reporting Person’s spouse through a retirement plan, 3,750 shares of common stock held as custodian for a grandchild, and 81,500 shares of common stock owned by Mr. P’s Foundation, a nonprofit corporation of which the Reporting Person is an affiliate. Page 3 of 6 Item 1. Security and Issuer (a) Name of Issuer: Provectus Biopharmaceuticals, Inc. (the “Issuer”) (b) Address of Issuer’s Principal Executive Office: 800 S. Gay Street, Suite 1610, Knoxville, TN 37929 (c) Title of Security: Common Stock, par value $0.001 per share (“Common Stock”) Item 2. Identity and Background (a) Name of Person Filing: Edward Pershing, CPA (the “Reporting Person”) (b) Business Address of Person Filing:800 S. Gay Street, Suite 1610, Knoxville, TN 37929 (c) Principal Occupation or Employment: Chairman and Chief Executive Officer of the Issuer, a clinical-stage biotechnology company. The address of the Issuer is 800 S. Gay Street, Suite 1610, Knoxville, TN 37929. (d) During the past five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws. (f) Citizenship: U.S.A. Item 3. Source and Amount of Funds or Other Con

View Full Filing

View this SC 13D filing on SEC EDGAR